gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · IONSHealthcarePharmaceuticals

Ionis Pharmaceuticals, Inc. Common Stock (IONS)

$40.15−0.67%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$40.15▼ 44.91% in range
Nov 4, 2025Low $40.15 · High $86.50Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Ionis Pharmaceuticals closed at $40.15 on Nov 4, down 0.67%, within 0.0% of its 52-week closing low. Volume of 4.1M shares was 1.48× its 20-day average (above normal).

Split-adjusted performance: -8.8% over one month, -47.8% over six months, -45.5% over one year.

In the quarter ended Jun 30, 2026, revenue was $267.95M, down 40.7% from a year earlier, with a net margin of -42.8%.

Short interest was 20.7M shares at the Oct 15 settlement, down 8.2% from the prior report (12.6% of float, 7.7 days to cover).

Market cap$6.67B166.2M shares
Revenue · quarter$267.9M−40.7% YoY
Diluted EPS$-0.69−198.6% YoY
P/E · TTM—P/S 7.6×
Net margin-42.8%Gross 99.0%
Dividend yieldNone
52-week range40.15 – 86.50−53.6% from high
Volume4.1M1.48× 20-day avg
Volatility · 60d43.5%Annualised
Short % of float12.6%7.7 days to cover
Net cash$732.0MCash $2.05B
Next earnings—Not scheduled
Split-adjusted performance
1W −10.6%1M −8.8%3M −26.3%6M −47.8%YTD −49.2%1Y −45.5%3Y −8.8%5Y +34.7%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum28
Revenue growth23
Net margin47
Value (low P/E)—
Size91

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short20.7M−8.2% vs prior
Days to cover7.7Settled Oct 15
% of float12.6%
Short vol. 10d39.3%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
IONSIonis Pharmaceuticals$40.15−0.67%−47.8%−40.7%−42.8%—$6.67B
ORKAOruka Therapeutics$101.41+1.87%+45.3%———$6.71BCompare
AMRXAmneal Pharmaceuticals$19.95−1.29%+46.5%+9.9%7.2%44.2$6.95BCompare
LGNDLigand Pharmaceuticals$316.13+0.83%+35.9%−31.8%−36.2%122.9$6.32BCompare
MIRMMirum Pharmaceuticals$96.97+11.42%−11.9%+39.6%−22.0%—$6.30BCompare
AXSMAxsome Therapeutics$137.00−1.87%−38.5%+51.9%−5.0%—$7.18BCompare
KNSAKiniksa Pharmaceuticals International$96.12+3.03%+65.1%+58.1%16.6%68.9$7.55BCompare
RYTMRhythm Pharmaceuticals$110.68+28.04%+14.6%+46.9%−70.7%—$7.62BCompare
ALKSAlkermes$45.89+0.44%+29.9%+21.8%3.4%—$7.70BCompare

News about Ionis Pharmaceuticals

All news →
Earnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to DeclineZacks Investment Research · Oct 28, 2026▼ NegativeIonis Delivers Positive Late-Stage Results for Two Partnered DrugsZacks Investment Research · Sep 23, 2026▲ PositiveInvestors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish OutlookThe Motley Fool · Sep 20, 2026NeutralOligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta TherapeuticsGlobeNewswire Inc. · Sep 15, 2026▲ PositiveIONS Secures FDA Nod for Rare Brain Disorder Drug ZanvastroZacks Investment Research · Sep 4, 2026Neutral

Quick answers

What does Ionis Pharmaceuticals do?
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases.
What is IONS's market cap?
$6.67B, based on the Nov 4 close of $40.15.
Does Ionis Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of IONS is sold short?
20.7M shares, 12.6% of float, as of Oct 15, 2026.
What sector is IONS in?
Healthcare, in the Pharmaceuticals industry.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

HQ: Carlsbad, CA1,402 employeesListed May 17, 1991ionis.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology